Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MP-Myeloma Regimen

Known as: Melphalan-Prednisone Regimen 
A regimen consisting of melphalan and prednisone used as induction treatment for multiple myeloma.
National Institutes of Health

Related topics

Related topics

4 relations
MelphalanMultiple MyelomaPrednisonemelphalan/prednisone protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple…
This phase I/II dose-escalation study investigated the all-oral ixazomib-melphalan-prednisone regimen, followed by single-agent… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2016
Review
2016
Treatment of Newly Diagnosed Elderly Multiple Myeloma.
Multiple myeloma (MM) is a disease of the elderly, with a median age at diagnosis of approximately 70 years old, and more than 30… Expand
Is this relevant?
2014
2014
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2014
2014
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies RUNNING HEAD : Chr 1 abnormalities in MM treated with new drugs
Multiple Myeloma is a plasma cell disorder, characterized by malignant plasma cell infiltration in the bone marrow, serum and/or… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Review
2013
Review
2013
Incorporating Novel Agents in the Management of Elderly Myeloma Patients
In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib… Expand
  • table 1
  • table 2
Is this relevant?
Review
2007
Review
2007
New therapies in multiple myeloma
The melphalan-prednisone regimen has been considered as standard therapy for patients with multiple myeloma (MM) for many years… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Review
2006
Review
2006
Thalidomide in multiple myeloma: past, present and future.
Thalidomide was introduced in the treatment of multiple myeloma in the late 1990s. Following the initial results, which… Expand
Is this relevant?
2002
2002
Current treatment strategies for multiple myeloma.
Until 1990, the melphalan-prednisone regimen was the standard treatment for multiple myeloma (MM). The role of alpha-interferon… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE